Median PFS ( progression-free survival ) was 1.2 years for capecitabine and 1.3 years for S-1 , with a hazard ratio ( S-1 / capecitabine ) of 0.85 ( 95 % confidence interval [ CI ] 0.52-1 .38 ) ( P = 0.48 by log-rank ) .